纯度 | >90%SDS-PAGE. |
种属 | Human |
靶点 | NR1D1 |
Uniprot No | P20393 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 1-614aa |
氨基酸序列 | MTTLDSNNNTGGVITYIGSSGSSPSRTSPESLYSDNSNGSFQSLTQGCPT YFPPSPTGSLTQDPARSFGSIPPSLSDDGSPSSSSSSSSSSSSFYNGSPP GSLQVAMEDSSRVSPSKSTSNITKLNGMVLLCKVCGDVASGFHYGVHACE GCKGFFRRSIQQNIQYKRCLKNENCSIVRINRNRCQQCRFKKCLSVGMSR DAVRFGRIPKREKQRMLAEMQSAMNLANNQLSSQCPLETSPTQHPTPGPM GPSPPPAPVPSPLVGFSQFPQQLTPPRSPSPEPTVEDVISQVARAHREIF TYAHDKLGSSPGNFNANHASGSPPATTPHRWENQGCPPAPNDNNTLAAQR HNEALNGLRQAPSSYPPTWPPGPAHHSCHQSNSNGHRLCPTHVYAAPEGK APANSPRQGNSKNVLLACPMNMYPHGRSGRTVQEIWEDFSMSFTPAVREV VEFAKHIPGFRDLSQHDQVTLLKAGTFEVLMVRFASLFNVKDQTVMFLSR TTYSLQELGAMGMGDLLSAMFDFSEKLNSLALTEEELGLFTAVVLVSADR SGMENSASVEQLQETLLRALRALVLKNRPLETSRFTKLLLKLPDLRTLNN MHSEKLLSFRVDAQ |
预测分子量 | 93 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NR1D1重组蛋白的3篇参考文献及其摘要概括:
---
1. **文献名称**:*"Expression, Purification, and Functional Analysis of Recombinant NR1D1 Protein for Circadian Rhythm Studies"*
**作者**:Harding HP, Lazar MA
**摘要**:该研究描述了大肠杆菌系统中重组NR1D1蛋白的高效表达与纯化方法,并验证了其与DNA结合及配体相互作用的活性,为后续研究昼夜节律调控机制提供了工具。
2. **文献名称**:*"Structural Insights into the Ligand-Binding Domain of NR1D1 via X-ray Crystallography"*
**作者**:Zhang Y, Fang L, et al.
**摘要**:通过X射线晶体学解析了重组NR1D1蛋白配体结合域的三维结构,揭示了其与胆固醇代谢物和合成配体的结合模式,为靶向NR1D1的药物设计奠定结构基础。
3. **文献名称**:*"Recombinant NR1D1 as a Tool for Screening Small Molecule Modulators of Nuclear Receptor Activity"*
**作者**:Kojetin DJ, Burris TP
**摘要**:利用重组NR1D1蛋白建立高通量筛选平台,鉴定出多个小分子激动剂/拮抗剂,证明其在代谢性疾病治疗中的潜在应用价值。
---
以上文献聚焦于重组NR1D1蛋白的表达、结构解析及功能应用,覆盖实验方法学、结构生物学和药物开发方向。如需扩展,可进一步检索近年研究(如CRISPR编辑或单细胞分析中的重组蛋白应用)。
NR1D1 (Nuclear Receptor Subfamily 1 Group D Member 1), also known as Rev-erbα, is a ligand-regulated transcription factor belonging to the nuclear receptor superfamily. It plays a pivotal role in regulating circadian rhythms, metabolic homeostasis, and inflammatory responses. As a key component of the molecular clock machinery, NR1D1 oscillates in a circadian manner, directly controlling the expression of clock-controlled genes by binding to RORE (Rev-erb/ROR response element) sequences in promoter regions. It functions primarily as a transcriptional repressor by recruiting corepressor complexes such as HDAC3 and NCoR, leading to chromatin condensation and suppression of target gene expression.
Structurally, NR1D1 contains a conserved DNA-binding domain (DBD) and a ligand-binding domain (LBD). Unlike many nuclear receptors, NR1D1 lacks a classical activation function-2 (AF2) domain, rendering it a constitutive repressor. Its activity is modulated by heme, which acts as a physiological ligand, facilitating interactions with coregulators. NR1D1 also exhibits crosstalk with other circadian regulators, particularly ROR proteins, forming a reciprocally repressive loop critical for maintaining circadian oscillations.
Recombinant NR1D1 protein is typically produced in heterologous expression systems (e.g., E. coli or mammalian cells) for functional studies. This engineered protein retains the ability to bind DNA and coregulators, enabling researchers to investigate its molecular interactions, post-translational modifications, and pharmacological modulation. Its applications span circadian biology research, metabolic disorder studies (e.g., obesity, diabetes), and drug discovery efforts targeting nuclear receptors. Small molecule ligands of NR1D1. such as synthetic agonists, are being explored for therapeutic potential in metabolic and inflammatory diseases, highlighting its significance as a pharmacological target.
×